<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814073</url>
  </required_header>
  <id_info>
    <org_study_id>AB06006</org_study_id>
    <nct_id>NCT00814073</nct_id>
  </id_info>
  <brief_title>Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis</brief_title>
  <acronym>AB06006</acronym>
  <official_title>Randomized, Placebo-controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib at 6 mg/kg/Day to Placebo in Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the safety and efficacy of masitinib (AB1010) to
      placebo in patients with mastocytosis with handicap.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a prospective, multicenter, randomized, placebo-controlled, parallel-group, phase 3
      study, conducted in 15 countries, evaluating the efficacy and safety of masitinib (6
      mg/kg/day administered orally in two daily intakes over 24-weeks with a double-blind
      extension period possible) for the treatment of indolent systemic mastocytosis, smoldering
      mastocytosis or cutaneous mastocytosis, in patients with mast cells mediator release symptoms
      that are refractory to conventional symptomatic treatment.

      A study protocol amendment restricted enrolment to patients with severe indolent and
      smoldering systemic mastocytosis. The objective of this phase 3 study was therefore to
      evaluate masitinib efficacy and safety in severe systemic mastocytosis patients, with or
      without D816V mutation of c-Kit. The primary objective of the phase 3 study was to detect a
      statistically significant difference between masitinib (plus optimal concomitant symptomatic
      treatments) and placebo (plus optimal concomitant symptomatic treatments) in cumulative
      response on four severe symptoms, referred to also as handicaps.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative response (4R75%)</measure>
    <time_frame>24 weeks</time_frame>
    <description>The prospectively declared primary endpoint (4R75%) was cumulative response in at least one of four severe baseline symptoms of mast cell mediator release (pruritus, flushes, depression, or asthenia). Response was defined as a 75% improvement from baseline for any of these four symptoms. Cumulative response was defined as the number of actual responses between weeks 8 and 24, divided by the total number of possible responses over the same treatment period (ie, with five scheduled visits, each patient had a maximum of five to 20 possible responses depending on the number of severe baseline symptoms).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative response (3R75%)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cumulative response in at least one of three severe baseline symptoms (pruritus, flushes, or depression)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative response (2R75%)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cumulative response in at least one of three severe baseline symptoms (pruritus or flushes)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Indolent Systemic Mastocytosis</condition>
  <arm_group>
    <arm_group_label>Masitinib &amp; BSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Masitinib (6 mg/kg/day) administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &amp; BSC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masitinib</intervention_name>
    <description>Masitinib 6 mg/kg/day</description>
    <arm_group_label>Masitinib &amp; BSC</arm_group_label>
    <other_name>AB1010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo &amp; BSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Supportive Care</intervention_name>
    <description>Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglicate, antidepressants, leukotriene antagonists, interferon-alpha, 2-CdA, and corticosteroids.</description>
    <arm_group_label>Masitinib &amp; BSC</arm_group_label>
    <arm_group_label>Placebo &amp; BSC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with one of the following documented mastocytosis as per WHO classification:
             Smouldering Systemic Mastocytosis, Severe Indolent Mastocytosis

          2. Patient with documented mastocytosis and evaluable disease based upon histological
             criteria: typical infiltrates of mast cells in a multifocal or diffuse pattern in skin
             and/or bone marrow biopsy

          3. Patient with documented treatment failure of his/her handicap(s) with at least one of
             the following therapy used at optimized dose: Anti H1, Anti H2, Proton pump inhibitor,
             Osteoclast inhibitor, Cromoglycate Sodium, Antileukotriene

          4. Handicapped status defined as at least two of the following handicaps, including at
             least one among pruritus, flushes, depression and fatigue: pruritus score ≥ 9, number
             of flushes per week ≥ 8, Hamilton rating scale for depression (HAMD-17) score ≥ 19,
             number of stools per day ≥ 4, number of mictions per day ≥ 8, Fatigue Impact Scale
             total score (asthenia) ≥ 75

          5. Patients with OPA ≥ 2 (moderate to intolerable general handicap)

          6. ECOG ≤ 2

          7. Patient with adequate organ function

        Exclusion Criteria:

          1. Patient with one of the following mastocytosis: Cutaneous Mastocytosis, Not documented
             Smouldering Systemic Mastocytosis or Indolent Systemic Mastocytosis, Systemic
             Mastocytosis with an Associated clonal Hematologic Non Mast cell lineage Disease
             (SM-AHNMD), Mast cell leukemia (MCL), Aggressive systemic mastocytosis (ASM)

          2. Previous treatment with any Tyrosine Kinase Inhibitor

          3. Patient with recent cardiac history of: Acute coronary syndrome, Acute heart failure,
             Significant ventricular arrhythmia; patient with cardiac failure class III or IV;
             Syncope without known aetiology within 3 months, uncontrolled severe hypertension.

          4. Patient with any condition that the physician judges could be detrimental to subjects
             participating in this study; including any clinically important deviations from normal
             clinical laboratory values or concurrent medical events Previous treatment

          5. Change in the symptomatic treatment of mastocytosis or administration of any new
             treatment of mastocytosis within 4 weeks prior to baseline

          6. Treatment with any investigational agent within 4 weeks prior to baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Lortholary, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Necker, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis Health System , Department of Dermatology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Centre</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Central</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital l'Archet II</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Milétrie</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital des Hauts Clos</name>
      <address>
        <city>Troyes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985971/</url>
    <description>Publication of results</description>
  </link>
  <reference>
    <citation>Arock M. A new therapeutic advance for symptomatic systemic mastocytosis? Lancet. 2017 Feb 11;389(10069):576-578. doi: 10.1016/S0140-6736(16)31655-5. Epub 2017 Jan 7.</citation>
    <PMID>28069280</PMID>
  </reference>
  <results_reference>
    <citation>Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, Niedoszytko M, Barete S, Verstovsek S, Grattan C, Damaj G, Canioni D, Fraitag S, Lhermitte L, Georgin Lavialle S, Frenzel L, Afrin LB, Hanssens K, Agopian J, Gaillard R, Kinet JP, Auclair C, Mansfield C, Moussy A, Dubreuil P, Hermine O. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet. 2017 Feb 11;389(10069):612-620. doi: 10.1016/S0140-6736(16)31403-9. Epub 2017 Jan 7.</citation>
    <PMID>28069279</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>December 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2008</study_first_posted>
  <disposition_first_submitted>December 12, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>December 12, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 14, 2018</disposition_first_posted>
  <last_update_submitted>November 29, 2019</last_update_submitted>
  <last_update_submitted_qc>November 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mastocytosis with handicap</keyword>
  <keyword>Mastocytosis</keyword>
  <keyword>Mast cell</keyword>
  <keyword>Mast cell infiltration</keyword>
  <keyword>Skin</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>Pruritus</keyword>
  <keyword>Flushes</keyword>
  <keyword>c-kit</keyword>
  <keyword>c-kit mutation</keyword>
  <keyword>Wild Type</keyword>
  <keyword>Mutation Asp-816-Val(D816V)</keyword>
  <keyword>Indolent systemic mastocytosis</keyword>
  <keyword>smoldering systemic mastocytosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Mastocytosis, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

